LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply
AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.
-
Filed today
-
Companies tracked
NSE & BSE
Listed on
👋Welcome back, there - you're tracking 0 companies
🔔Sign in free to track companies and get alerts the moment they file
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors
Latest Filings -
📋 Filing Types Available on ForgeUp Filings
Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Hikal Ltd reported higher sales and a much smaller loss in its latest quarter, securing a new contract.
🤖 AI Summary
Hikal Ltd reported consolidated revenue of ₹434 crore for Q2 FY27, a 36% increase year-on-year.
Consolidated PAT stood at ₹(6) crore in Q2 FY27, an 83% reduction in loss from ₹(35) crore in Q2 FY26.
Pharmaceuticals business revenue grew 47% YoY to ₹278 crore, driven by API recovery and CDMO execution.
Crop-Protection business revenue increased 21% YoY to ₹156 crore, with own product sales up 11% YoY.
Hikal signed a multi-year CDMO contract with a Europe-based global agrochemical company for a specialized product.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Revenue (Q2 FY27)
₹ 434 crore
+36%
Consolidated EBITDA (Q2 FY27)
₹ 45 crore
+543%
Consolidated PAT (Q2 FY27)
₹ (6) crore
+83%
Pharmaceuticals Revenue (Q2 FY27)
₹ 278 crore
+47%
Crop-Protection Revenue (Q2 FY27)
₹ 156 crore
+21%
🏢 How This Affects the Company
📈
Business Impact
Consolidated revenue increased 36% year-on-year, indicating a recovery in established API portfolio and continued CDMO execution across global markets. The new multi-year CDMO contract strengthens the company's agrochemical business pipeline.
💰
Financial Impact
The consolidated PAT improved significantly, with the net loss reducing from ₹(35) crore in Q2 FY26 to ₹(6) crore in Q2 FY27. EBITDA for the quarter stood at ₹45 crore, reflecting stronger operational performance.
⚙️
Operational Impact
Commercial production commenced at the new Personal Care facility at Panoli, strengthening the UV filter portfolio. The Bengaluru API facility received GMP certification from Swissmedic authorities, expanding regulatory approvals.
⚠️
Risk Impact
The Crop-Protection business continues to face challenges from elevated raw material and energy prices, Chinese competition, and deferred demand impacting margins.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the improved financial performance, with consolidated EPS improving from ₹(2.83) in Q2 FY26 to ₹(0.49) in Q2 FY27.
🔍
Management Signal
Management is focused on business recovery, operational efficiency, expanding CDMO opportunities, and new product commercialization to improve profitability.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
Updates on the new multi-year CDMO contract's execution and revenue contribution.
Progress on Personal Care commercial production and customer approvals for new UV filters.
MEDIUM RISKOngoing challenges in Crop-Protection business due to elevated raw material costs and competition continue to impact margins.
💡 Investor Takeaway
Hikal Ltd reported Q2 FY27 consolidated revenue of ₹434 crore, marking a 36% YoY increase. Net loss significantly reduced to ₹(6) crore from ₹(35) crore in Q2 FY26. The Pharmaceuticals segment grew 47% YoY, and a new multi-year CDMO contract was signed.
⚖️ Strengths & Concerns
✅ Positives
Consolidated Revenue grew 36% YoY to ₹434 crore in Q2 FY27, supported by recovery in API and CDMO execution.
Net loss significantly reduced to ₹(6) crore in Q2 FY27 from ₹(35) crore in Q2 FY26, an 83% improvement.
⚠️ Concerns
Crop-Protection margins were impacted by elevated raw material prices, Chinese competition, and deferred demand.
The company reported a consolidated PAT of ₹(6) crore, indicating continued net loss for the quarter.
📅 Company Track Record
Hikal Ltd previously reported a standalone net loss of Rs. 62 Million on Rs. 4,342 Million revenue for Q2 FY27 and Rs. 75 Million loss on Rs. 4,028 Million revenue for Q1 FY27. This quarter's consolidated results show a recovery compared to the previous Q2 FY26 consolidated net loss of Rs. 35 crore.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Hikal Ltd's consolidated revenue in Q2 FY27?
Hikal Ltd reported consolidated revenue of ₹434 crore for the quarter ended September 30, 2026 (Q2 FY27).
What was Hikal Ltd's consolidated net profit (PAT) in Q2 FY27?
Hikal Ltd's consolidated PAT for Q2 FY27 was ₹(6) crore, showing an 83% reduction in net loss compared to ₹(35) crore in Q2 FY26.
How did Hikal Ltd's Pharmaceuticals segment perform in Q2 FY27?
The Pharmaceuticals segment revenue grew by 47% year-on-year to ₹278 crore in Q2 FY27, driven by recovery in the established API portfolio and CDMO execution.
Did Hikal Ltd sign any new contracts in Q2 FY27?
Yes, Hikal Ltd signed a multi-year CDMO contract with a Europe-based global agrochemical company for the manufacture and supply of a specialized product to international markets.
What was Hikal Ltd's EBITDA in Q2 FY27?
Hikal Ltd's consolidated EBITDA for Q2 FY27 stood at ₹45 crore, reflecting a margin of 10.3%.
Questions based on this BSE filing only. For information purposes.
There are 32,000 more, and one of them is about a company you own
Follow a company and we'll email you the moment it files
again - explained, not just forwarded. Free.
Follow companies and get filings by email
Save any filing to read later
Two full AI analyses every month, free
No card needed. Sign in with Google in two taps.
⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔖
Save filings you care about
Sign in free to save any filing and get notified when the same company files again.
🔖
Save This Filing
Sign in with Google to save this filing and get notified when this company files again. Free, takes 5 seconds.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.